Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
BioSpace
After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other companies, including Incyte, Novartis and UCB, have recently notched clinical
pharminent
April 8, 2026 (Last updated: April 8, 2026)
BioSpace
After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other companies, including Incyte, Novartis and UCB, have recently notched clinical